These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 15967825)

  • 21. Application of natural killer T cells in antitumor immunotherapy.
    Hong C; Park SH
    Crit Rev Immunol; 2007; 27(6):511-25. PubMed ID: 18197797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides.
    Ortaldo JR; Young HA; Winkler-Pickett RT; Bere EW; Murphy WJ; Wiltrout RH
    J Immunol; 2004 Jan; 172(2):943-53. PubMed ID: 14707067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of natural killer (NK) T cells during murine cytomegalovirus infection enhances the antiviral response mediated by NK cells.
    van Dommelen SL; Tabarias HA; Smyth MJ; Degli-Esposti MA
    J Virol; 2003 Feb; 77(3):1877-84. PubMed ID: 12525622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation-induced NKT cell hyporesponsiveness protects from alpha-galactosylceramide hepatitis and is independent of active transregulatory factors.
    Biburger M; Tiegs G
    J Leukoc Biol; 2008 Jul; 84(1):264-79. PubMed ID: 18407967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes.
    Sharif S; Arreaza GA; Zucker P; Mi QS; Sondhi J; Naidenko OV; Kronenberg M; Koezuka Y; Delovitch TL; Gombert JM; Leite-De-Moraes M; Gouarin C; Zhu R; Hameg A; Nakayama T; Taniguchi M; Lepault F; Lehuen A; Bach JF; Herbelin A
    Nat Med; 2001 Sep; 7(9):1057-62. PubMed ID: 11533711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Ex vivo expansion of Valpha24 natural killer T cells with alpha-galactosylceramide].
    Huang Y; Jiang EL; Zhou Z; He Y; Wang M; Liu QG; Zhai WJ; Han MZ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Jun; 27(3):315-20. PubMed ID: 16038267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced suppression of pulmonary metastasis of malignant melanoma cells by combined administration of alpha-galactosylceramide and interleukin-18.
    Nishio S; Yamada N; Ohyama H; Yamanegi K; Nakasho K; Hata M; Nakamura Y; Fukunaga S; Futani H; Yoshiya S; Ueda H; Taniguchi M; Okamura H; Terada N
    Cancer Sci; 2008 Jan; 99(1):113-20. PubMed ID: 17949451
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Natural killer T cells from interleukin-4-deficient mice are defective in early interferon-gamma production in response to alpha-galactosylceramide.
    Togashi Y; Chamoto K; Wakita D; Tsutsumi N; Iwakura Y; Matsubara N; Kitamura H; Nishimura T
    Cancer Sci; 2007 May; 98(5):721-5. PubMed ID: 17359285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activated iNKT cells promote Vγ9Vδ2-T cell anti-tumor effector functions through the production of TNF-α.
    Schneiders FL; de Bruin RC; Santegoets SJ; Bonneville M; Scotet E; Scheper RJ; Verheul HM; de Gruijl TD; van der Vliet HJ
    Clin Immunol; 2012 Feb; 142(2):194-200. PubMed ID: 22122798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of clinical and immunological effects of intravenous and intradermal administration of α-galactosylceramide (KRN7000)-pulsed dendritic cells.
    Nicol AJ; Tazbirkova A; Nieda M
    Clin Cancer Res; 2011 Aug; 17(15):5140-51. PubMed ID: 21653690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
    Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
    Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs.
    Fujii S; Shimizu K; Kronenberg M; Steinman RM
    Nat Immunol; 2002 Sep; 3(9):867-74. PubMed ID: 12154358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancement of the synthetic ligand-mediated function of liver NK1.1Ag+ T cells in mice by interleukin-12 pretreatment.
    Habu Y; Uchida T; Inui T; Nakashima H; Fukasawa M; Seki S
    Immunology; 2004 Sep; 113(1):35-43. PubMed ID: 15312134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dendritic cell maturation by CD11c- T cells and Valpha24+ natural killer T-cell activation by alpha-galactosylceramide.
    Ishikawa E; Motohashi S; Ishikawa A; Ito T; Uchida T; Kaneko T; Tanaka Y; Horiguchi S; Okamoto Y; Fujisawa T; Tsuboi K; Taniguchi M; Matsumura A; Nakayama T
    Int J Cancer; 2005 Nov; 117(2):265-73. PubMed ID: 15900581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD1d-mediated stimulation of natural killer T cells selectively activates hepatic natural killer cells to eliminate experimentally disseminated hepatoma cells in murine liver.
    Miyagi T; Takehara T; Tatsumi T; Kanto T; Suzuki T; Jinushi M; Sugimoto Y; Sasaki Y; Hori M; Hayashi N
    Int J Cancer; 2003 Aug; 106(1):81-9. PubMed ID: 12794761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. α-Galactosylceramide but not phenyl-glycolipids induced NKT cell anergy and IL-33-mediated myeloid-derived suppressor cell accumulation via upregulation of egr2/3.
    Huang JR; Tsai YC; Chang YJ; Wu JC; Hung JT; Lin KH; Wong CH; Yu AL
    J Immunol; 2014 Feb; 192(4):1972-81. PubMed ID: 24465013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity.
    Van den Bergh J; Willemen Y; Lion E; Van Acker H; De Reu H; Anguille S; Goossens H; Berneman Z; Van Tendeloo V; Smits E
    Oncotarget; 2015 Dec; 6(42):44123-33. PubMed ID: 26675759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human invariant valpha24+ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells.
    Nicol A; Nieda M; Koezuka Y; Porcelli S; Suzuki K; Tadokoro K; Durrant S; Juji T
    Immunology; 2000 Feb; 99(2):229-34. PubMed ID: 10692041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with alpha-galactosylceramide.
    Toura I; Kawano T; Akutsu Y; Nakayama T; Ochiai T; Taniguchi M
    J Immunol; 1999 Sep; 163(5):2387-91. PubMed ID: 10452972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective ability of mouse CD1 to present glycolipids: alpha-galactosylceramide specifically stimulates V alpha 14+ NK T lymphocytes.
    Burdin N; Brossay L; Koezuka Y; Smiley ST; Grusby MJ; Gui M; Taniguchi M; Hayakawa K; Kronenberg M
    J Immunol; 1998 Oct; 161(7):3271-81. PubMed ID: 9759842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.